In a significant move for Spyre Therapeutics, Inc. (NASDAQ: SYRE), Chief Executive Officer Cameron Turtle has executed a series of stock sales totaling $1,070,507. The transactions were finalized on May 1, 2026, involving the sale of 15,000 shares of common stock. These trades were not spontaneous; rather, they were conducted according to a Rule 10b5-1 trading plan that Mr. Turtle had established on June 20, 2025.
The liquidation was managed through several distinct transactions throughout the day, with share prices fluctuating between $69.54 and $74.96. A detailed breakdown of these individual sales reveals the following structure:
- 5,300 shares were sold at a weighted average price of $69.54, with individual transaction prices ranging from $69.25 to $70.24.
- 3,600 shares were traded at an average price of $70.77, with prices between $70.30 and $71.28.
- 1,000 shares were sold at an average of $71.76 (range: $71.41 to $72.27).
- 3,100 shares moved at an average price of $73.14 (range: $72.75 to $73.74).
- 1,700 shares were sold at an average of $74.23 (range: $73.95 to $74.94).
- 300 shares were sold at an average price of $74.96 (range: $74.95 to $74.96).
Following this divestment, Mr. Turtle maintains a direct ownership stake of 612,540 shares in Spyre Therapeutics. This holdings figure includes 101,653 shares that are scheduled for monthly vesting through November 2026, provided he continues his service to the organization.
The timing of this sale coincides with a period of intense market activity and rapid valuation growth for SYRE. Over the past year, the stock has surged by 359%, placing it near its 52-week high of $76. However, analysis suggests potential volatility; current data indicates the stock may be overvalued relative to its Fair Value, with RSI indicators pointing toward overbought territory.
Spyre Therapeutics has also been highly active in capital markets recently. The company successfully completed a large stock offering, raising roughly $463.5 million by selling 7,475,000 shares at $62.00 per share. This specific offering included an option for underwriters to buy an additional 975,000 shares. This follows other significant capital-raising efforts, including a $403 million public stock offering (which carried a $60.5 million underwriter option) and a separate $300 million stock offering.
Market sentiment has seen professional interest as well. Analyst Martin Auster noted that Raymond James initiated coverage on the company with a strong buy rating, setting a price target of $80.00. These varied financial activities highlight a period of significant capital restructuring and analyst scrutiny for the biotechnology firm.